Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET

Company Participants

Nicole Oschner - Vice President of Investor Relations and Corporate Communications
Neil McFarlane - President and Chief Executive Officer
LaDuane Clifton - Chief Financial Officer
Josh Schafer - Chief Commercial Officer and Executive Vice President of Business Development

Conference Call Participants

Louise Chen - Cantor Fitzgerald
Tim Lugo - William Blair
Oren Livnat - H.C. Wainwright

Operator

Hello, and thank you for joining the Zevra Therapeutics Q2 2024 Financial Results and Corporate Highlights Call. Today's call is being recorded and will be made available on the company's website following the conclusion of the call.

With that, I will now turn the call over to Nicole Oschner, Vice President of Investor Relations and Corporate Communications for Zevra Therapeutics.

Nicole Oschner

Good afternoon, and thank you for joining us today to review Zevra Therapeutics progress in the second quarter of 2024 outlining our clinical advances, operational achievements, and financial results.

Before we get started, let me take a moment to provide some important information. I encourage you to access the news release which was published this afternoon and is available in the Investors Section of the Zevra website.

As we begin our call, it's important to highlight that certain information covered in today's discussions will include forward-looking statements. We caution listeners that actual results could differ materially from these stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. Forward-looking statements are not promises or guarantees and are inherently subject to risks, uncertainties and other significant factors that may lead to actual results differing materially from those projections made. These forward-looking statements are qualified by the cautionary statements contained in the Risk Factors section in our most recent quarterly report on Form 10-Q and our other filings with the SEC annual report on Form 10-K.

I'm pleased to welcome Zevra's management team members participating in today's call. I'm joined by Neil McFarlane, President and Chief Executive Officer; LaDuane Clifton, our Chief Financial Officer; Josh Schafer, our Chief Commercial Officer and Executive Vice President of Business Development; and Adrian Quartel, our Chief Medical Officer.

Now I'll turn the call over to Neil.

Neil McFarlane

Thank you, Nicole, and thank you all for making the time to join us today. During the second quarter, we made steady progress executing on our strategic objectives, preparing for the advisory committee meeting and the potential launch of arimoclomol, driving the launch of OLPRUVA and advancing KP1077 for sleep disorders.